Resistance exercise reduced lean mass loss in adults on tirzepatide in a 40-week trial
In 120 adults on tirzepatide, thrice-weekly resistance exercise reduced loss of lean soft tissue mass and improved strength, with no significant difference in weight or fat mass loss.

At a glance
- Total lean soft tissue mass fell with tirzepatide alone (-4.67 kg) and fell less with added resistance exercise (-3.57 kg), P < 0.001.
- Weight loss and fat mass loss were not significantly different between the two groups.
- Muscle strength fell with tirzepatide alone and rose with resistance exercise. Hard clinical outcomes were not reported.
Key result
Adding resistance exercise reduced lean mass loss on tirzepatide (-3.57 vs -4.67 kg).
Change in total lean soft tissue mass, 40 weeks
The study
This is a two-arm randomised controlled trial published in Nature Medicine. It asked whether adding resistance exercise (REx) to tirzepatide (T) protects lean soft tissue mass during weight loss. Incretin-based obesity treatment lowers fat mass, but it also lowers lean soft tissue mass. The authors note that this may weaken skeletal muscle function.
A total of 120 adults with overweight or obesity were treated with tirzepatide. They were randomised to thrice-weekly resistance exercise training or to usual activities for 40 weeks. The primary outcomes were change in total fat mass and change in total lean soft tissue mass. The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12623001236684).
What they found
The authors report that tirzepatide was safe and that most participants tolerated up-titration to 15 mg weekly. Adherence to resistance exercise was 91%.
- Body weight: it fell in both groups (T = -22.61 kg, T+REx = -22.28 kg). The groups were not significantly different (P = 0.694).
- Total fat mass: it fell in both groups (T = -17.19 kg, T+REx = -17.98 kg), P = 0.700. The between-group difference was -0.77 kg (95% CI -2.14 kg to 0.60 kg).
- Total lean soft tissue mass: it fell in both groups, but the fall was smaller with exercise (T = -4.67 kg, T+REx = -3.57 kg), P < 0.001. The between-group difference was 1.09 kg (95% CI 0.43-1.75 kg).
- Appendicular lean soft tissue mass: it fell in both groups, and the fall was smaller with exercise (T = -3.55 kg, T+REx = -2.92 kg), P < 0.001.
- Strength: with tirzepatide alone, strength fell (bench press -4.09 kg, lat pulldown -4.42 kg, knee extension -4.42 kg). With added exercise, strength rose (+4.68 kg, +8.58 kg, +5.88 kg, respectively). All differences versus tirzepatide alone had P < 0.001.
The authors conclude that resistance exercise is an effective adjunct to tirzepatide.
How much weight to give it
Randomisation is a strong design for this question. The primary outcomes are clearly stated and the trial is registered. Adherence to exercise was high.
There are limits. The trial had 120 participants and lasted 40 weeks. Lean soft tissue mass and strength test results are surrogate measures. The abstract does not report outcomes such as falls, fractures, disability or quality of life. It also does not report what happens to lean mass or strength after the 40 weeks, or after tirzepatide is stopped.
The abstract does not report funding, blinding, drop-outs, participant age, sex or diabetes status, or details of adverse events. Whether the 1.09 kg difference in lean soft tissue mass matters clinically is not shown here. Findings from one trial should be confirmed in other studies.
For your clinic
These results suggest that a structured resistance exercise programme may limit lean mass loss and protect strength in people losing weight on tirzepatide. This supports discussing resistance exercise as part of obesity care, alongside drug treatment.
Before changing practice, read the full paper. Check who was enrolled and what safety data were reported. The abstract does not describe how the exercise programme was delivered or supervised, or what resources it required. Exercise advice for any individual patient should take into account their other conditions and physical fitness.
Source
Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.
Green DJ, Haynes A, Underwood DR et al.. Nature medicine. 9 November 2026
Cite this report: Diabesity Rounds. Resistance exercise reduced lean mass loss in adults on tirzepatide in a 40-week trial. 2026. doi:10.5281/zenodo.24236973
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on obesity medicine
- CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9Randomised trial · 16 November 2026
- Trevogrumab reduced lean mass loss on semaglutide in phase 2 trialRandomised trial · 13 November 2026
- Survodutide not linked to higher cardiovascular risk in phase 3 obesity trialRandomised trial · 11 November 2026
- Retatrutide eased knee osteoarthritis pain more than placebo in two phase 3 trialsRandomised trial · 10 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.